Zhen Yu

List of Publications by Year
in descending order

20	209	1040056 9	1125743 13
papers	citations	h-index	g-index

21	21	21	338
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. Journal of Clinical Investigation, 2022, 132, .	8.2	30
2	Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment. Scientific Reports, 2020, 10, 20508.	3.3	22
3	Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. Molecular Cancer Research, 2020, 18, 1063-1073.	3.4	22
4	Raman spectroscopy-based biomarker screening by studying the fingerprint characteristics of chronic lymphocytic leukemia and diffuse large B-cell lymphoma. Journal of Pharmaceutical and Biomedical Analysis, 2020, 190, 113514.	2.8	20
5	Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genetics in Medicine, 2017, 19, 182-191.	2.4	17
6	Indirubin-3â€™-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. EBioMedicine, 2022, 78, 103950.	6.1	15
7	Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region. Oncotarget, 2017, 8, 98757-98770.	1.8	14
8	BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase. BMC Medical Genetics, 2017, 18, 16.	2.1	13
9	Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma. Cancer Gene Therapy, 2020, 27, 869-877.	4.6	11
10	The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study. International Journal of Hematology, 2017, 106, 418-425.	1.6	8
11	Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 156-165.	2.2	8
12	Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e652-e659.	0.4	7
13	Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia. Chinese Medical Journal, 2017, 130, 135-142.	2.3	6
14	Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. BMC Cancer, 2015, 15, 555.	2.6	5
15	Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders. Oncotarget, 2018, 9, 3353-3364.	1.8	5
16	Four and a Half LIM Domains Protein 2 Mediates Bortezomib-Induced Osteogenic Differentiation of Mesenchymal Stem Cells in Multiple Myeloma Through p53 Signaling and Î²-Catenin Nuclear Enrichment. Frontiers in Oncology, 2021, 11, 729799.	2.8	3
17	TOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia. Chinese Medical Journal, 2020, 133, 2090-2097.	2.3	1
18	Clonal Heterogeneity and Evolutionary Phylogeny of Critical Cytogenetic Aberrations in Multiple Myeloma. Blood, 2021, 138, 1608-1608.	1.4	1

#	Article	IF	Citations
19	Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant. Annals of Hematology, 2022, 101, 1201-1210.	1.8	1
20	Gene Mutation Signature and Its Pathogenesis Role in Chronic Lymphocytic Leukemia in China: Different from the Western Reports. Blood, 2016, 128, 4360-4360.	1.4	0